Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age

NCT04144179 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Quadrivalent RIV with H3 strain 1
BIOLOGICAL: Quadrivalent RIV with H3 strain 2
BIOLOGICAL: Quadrivalent RIV with H3 strain 3
BIOLOGICAL: Quadrivalent RIV with H3 strain 4
BIOLOGICAL: Quadrivalent RIV with 2018-2019 NH H3 strain

Sponsor

Sanofi Pasteur, a Sanofi Company